Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 14/20 | 0.46 |
| ▸ | CACNA1I | Q9P0X4 | 10/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18838425 | 0.93 | KCNH2 (0.47) | KCNH2CACNA1ICACNA1HCYP2D6SCN5A | |
| SCHEMBL18838395 | 0.88 | KCNH2 (0.46) | KCNH2CACNA1ICACNA1HCYP2D6SCN5A | |
| SCHEMBL18860276 | 0.86 | CHRNA7 (0.46) | KCNH2CACNA1I | |
| SCHEMBL18838432 | 0.84 | CYP2D6 (0.43) | CYP2D6SCN5A | |
| SCHEMBL18860337 | 0.83 | KCNH2 (0.59) | KCNH2CACNA1ICACNA1HCYP2D6 | |
| SCHEMBL18860342 | 0.82 | MCHR1 (0.47) | KCNH2CACNA1ICYP2D6 | |
| SCHEMBL18860345 | 0.81 | CACNA1I (0.59) | KCNH2CACNA1ICACNA1HCYP2D6 | |
| SCHEMBL29361615 | 0.80 | CHRNA7 (0.47) | KCNH2CACNA1I | |
| SCHEMBL18838363 | 0.80 | CHRNA7 (0.47) | KCNH2CACNA1I | |
| SCHEMBL18860333 | 0.79 | KCNH2 (0.57) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2017083867-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | KCNH2 55/4885CACNA1I 1/4885CACNA1H 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.